Evidence map›Paper›PMID 37240315›Full record

ArticleInternational journal of molecular sciences2023

SIRT2 Deficiency Aggravates Diet-Induced Nonalcoholic Fatty Liver Disease through Modulating Gut Microbiota and Metabolites.

Xingyu Li, Yimeng Du, Chunyuan Xue, Xiaofeng Kang, Chao Sun, Huanyan Peng, Liaoxin Fang, Yuchen Han, Xiaojie Xu, Caiyan Zhao

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. CD38 Inhibition Enhances FXR Signaling in Male Rats With Diabetic Steatohepatitis Through SIRT1-Dependent Suppression of NLRP3.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Frontiers in pharmacology · 2025
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Frontiers in microbiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Xingyu LiDepartment of Infectious Diseases, The Third Hospital of Hebei Medical University, Shijiazhuang 050011, China.ORCID 0009-0001-5126-2655
Yimeng DuDepartment of Genetic Engineering, Beijing Institute of Biotechnology, Beijing 100850, China.
Chunyuan XueDepartment of Genetic Engineering, Beijing Institute of Biotechnology, Beijing 100850, China.
Xiaofeng KangDepartment of Genetic Engineering, Beijing Institute of Biotechnology, Beijing 100850, China.
Chao SunDepartment of Genetic Engineering, Beijing Institute of Biotechnology, Beijing 100850, China.
Huanyan PengDepartment of Genetic Engineering, Beijing Institute of Biotechnology, Beijing 100850, China.
Liaoxin FangDepartment of Genetic Engineering, Beijing Institute of Biotechnology, Beijing 100850, China.
Yuchen HanDepartment of Genetic Engineering, Beijing Institute of Biotechnology, Beijing 100850, China.
Xiaojie XuDepartment of Genetic Engineering, Beijing Institute of Biotechnology, Beijing 100850, China.
Caiyan ZhaoDepartment of Infectious Diseases, The Third Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Beijing VDJBio (China) · CNHebei Medical University · CN

Funding

Beijing Natural Science Foundation-Haidian Joint Fund for Original Innovation L222072Beijing Nova Program 20220484176Foundation strengthening program 2020-JCJQ-ZD-253-04National Natural Science Foundation of China 82202852The Innovation Ability Promotion Project of Hebei Infectious Disease Clinical Medical Research Center 20577704D
6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD), characterized by excessive lipid accumulation in hepatocytes, is an increasing global healthcare burden. Sirtuin 2 (SIRT2) functions as a preventive molecule for NAFLD with incompletely clarified regulatory mechanisms. Metabolic changes and gut microbiota imbalance are critical to the pathogenesis of NAFLD. However, their association with SIRT2 in NAFLD progression is still unknown. Here, we report that SIRT2 knockout (KO) mice are susceptible to HFCS (high-fat/high-cholesterol/high-sucrose)-induced obesity and hepatic steatosis accompanied with an aggravated metabolic profile, which indicates SIRT2 deficiency promotes NAFLD-NASH (nonalcoholic steatohepatitis) progression. Under palmitic acid (PA), cholesterol (CHO), and high glucose (Glu) conditions, SIRT2 deficiency promotes lipid deposition and inflammation in cultured cells. Mechanically, SIRT2 deficiency induces serum metabolites alteration including upregulation of L-proline and downregulation of phosphatidylcholines (PC), lysophosphatidylcholine (LPC), and epinephrine. Furthermore, SIRT2 deficiency promotes gut microbiota dysbiosis. The microbiota composition clustered distinctly in SIRT2 KO mice with decreased

Indexed as

Gastrointestinal MicrobiomeNon-alcoholic Fatty Liver DiseaseAnimalsDietDiet, High-FatLipidsLiverMiceMice, Inbred C57BLSirtuin 2LipidsSirtuin 2gut microbiotametabolomicsnon-alcoholic fatty liver disease (NAFLD)non-alcoholic steatohepatitis (NASH)SIRT2

Identifiers

PMID37240315
PMCPMC10219207
OpenAlexW4377104055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.